{"entity":{"id":"wang-jie-cams","kind":"person","name":"Jie Wang","aka":[],"tldr":"Led the RATIONALE trials of tislelizumab in lung cancer and many other Chinese registrational NSCLC studies.","summary":"Jie Wang is Professor of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing. She led the RATIONALE-304 and RATIONALE-307 trials of tislelizumab, the PD-1 antibody from BeOne Medicines, formerly BeiGene, in non-small-cell lung cancer, and has been principal investigator on many other Chinese registrational lung cancer studies. These include EGFR tyrosine kinase inhibitor and ALK trials in non-small-cell lung cancer and studies of Chinese PD-1 antibodies in small-cell lung cancer. Her interests are lung cancer, immunotherapy, targeted therapy and clinical trials.","asOf":"2026-09-08","links":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20J%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20tislelizumab%20lung"}],"tags":[],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["tislelizumab"],"companies":["beone"],"institutions":["cams-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences","institutionId":"cams-cancer-hospital","specialisms":["Lung cancer","Immunotherapy","Targeted therapy","Clinical trials"],"profiles":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20J%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20tislelizumab%20lung"}],"papers":[{"title":"Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer","journal":"JAMA Oncology","year":2021,"doi":"10.1001/jamaoncol.2021.0366"},{"title":"Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel","journal":"JAMA Oncology","year":2019,"doi":"10.1001/jamaoncol.2018.7098"},{"title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","journal":"The Lancet Oncology","year":2022,"doi":"10.1016/s1470-2045(22)00224-8"}]},"route":"/people/wang-jie-cams/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}],"institution":[{"id":"cams-cancer-hospital","kind":"institution","name":"Cancer Hospital, Chinese Academy of Medical Sciences","route":"/institutions/cams-cancer-hospital/"}]}}